Long-term efficacy and safety of canakinumab in patients with TRAPS: results from a phase III trial
Gattorno M, Obici L, Calvo Penadés I, Kallinich T, Benseler S, Dekker E, Lévy J, De Benedetti F, Lachmann H
Arthritis Rheumatol · 2024
Key Findings
- ●>94% achieved no or minimal disease activity during 72-week extension
- ●69.8% had zero flares; 24.5% had one flare (vs baseline median 9/year)
- ●No new safety findings with long-term canakinumab
Referenced in (1 disease)
Validation history
Full log →No validation events recorded yet. Source will be checked on the next kipine-source-validator run.
ID: pmid-37668289DOI: 10.1002/art.42695PMID: 37668289